513 related articles for article (PubMed ID: 24038106)
21. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.
Nguyen R; Houston J; Chan WK; Finkelstein D; Dyer MA
Cancer Immunol Immunother; 2018 Apr; 67(4):615-626. PubMed ID: 29327110
[TBL] [Abstract][Full Text] [Related]
22. Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity.
Rigo V; Corrias MV; Orengo AM; Brizzolara A; Emionite L; Fenoglio D; Filaci G; Croce M; Ferrini S
Cancer Immunol Immunother; 2014 May; 63(5):501-11. PubMed ID: 24647609
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
24. Combining immunotherapy with high-dose radiation therapy (HDRT) significantly inhibits tumor growth in a syngeneic mouse model of high-risk neuroblastoma.
Boboila S; Okochi S; Banerjee D; Barton S; Street C; Zenilman AL; Wang Q; Gartrell RD; Saenger YM; Welch D; Wu CC; Kadenhe-Chiweshe A; Yamashiro DJ; Connolly EP
Heliyon; 2023 Jun; 9(6):e17399. PubMed ID: 37408891
[TBL] [Abstract][Full Text] [Related]
25. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.
Voeller J; Erbe AK; Slowinski J; Rasmussen K; Carlson PM; Hoefges A; VandenHeuvel S; Stuckwisch A; Wang X; Gillies SD; Patel RB; Farrel A; Rokita JL; Maris J; Hank JA; Morris ZS; Rakhmilevich AL; Sondel PM
J Immunother Cancer; 2019 Dec; 7(1):344. PubMed ID: 31810498
[TBL] [Abstract][Full Text] [Related]
26. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
27. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
Cheng M; Ahmed M; Xu H; Cheung NK
Int J Cancer; 2015 Jan; 136(2):476-86. PubMed ID: 24895182
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma.
Aiken TJ; Erbe AK; Zebertavage L; Komjathy D; Feils AS; Rodriguez M; Stuckwisch A; Gillies SD; Morris ZS; Birstler J; Rakhmilevich AL; Sondel PM
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618290
[TBL] [Abstract][Full Text] [Related]
29. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
[TBL] [Abstract][Full Text] [Related]
30. Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells.
Wierzbicki A; Gil M; Ciesielski M; Fenstermaker RA; Kaneko Y; Rokita H; Lau JT; Kozbor D
J Immunol; 2008 Nov; 181(9):6644-53. PubMed ID: 18941255
[TBL] [Abstract][Full Text] [Related]
31. Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular Immunotherapy.
Iguchi M; Yagyu S; Kambe K; Higashi M; Fumino S; Kishida T; Iehara T; Mazda O; Tajiri T
Anticancer Res; 2023 Jun; 43(6):2417-2424. PubMed ID: 37247922
[TBL] [Abstract][Full Text] [Related]
32. Natural antibody against neuroblastoma of TH-MYCN transgenic mice does not correlate with spontaneous regression.
Kawakubo N; Harada Y; Ishii M; Souzaki R; Kinoshita Y; Tajiri T; Taguchi T; Yonemitsu Y
Biochem Biophys Res Commun; 2018 Sep; 503(3):1666-1673. PubMed ID: 30054041
[TBL] [Abstract][Full Text] [Related]
33. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF
Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295
[TBL] [Abstract][Full Text] [Related]
34. Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma.
Carlson LM; Rasmuson A; Idborg H; Segerström L; Jakobsson PJ; Sveinbjörnsson B; Kogner P
Carcinogenesis; 2013 May; 34(5):1081-8. PubMed ID: 23349014
[TBL] [Abstract][Full Text] [Related]
35. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.
Terrile M; Bryan K; Vaughan L; Hallsworth A; Webber H; Chesler L; Stallings RL
PLoS One; 2011; 6(12):e28356. PubMed ID: 22164278
[TBL] [Abstract][Full Text] [Related]
36. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
[TBL] [Abstract][Full Text] [Related]
37. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.
Di Matteo S; Bilotta MT; Pelosi A; Haas D; Theinert T; Weber G; Schlegel PG; Berg M; Moretta L; Maggi E; Azzarone B; Vacca P; Tumino N; Caruana I
Front Immunol; 2024; 15():1382931. PubMed ID: 38736882
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma.
Nguyen R; Moustaki A; Norrie JL; Brown S; Akers WJ; Shirinifard A; Dyer MA
Clin Cancer Res; 2019 Dec; 25(24):7554-7564. PubMed ID: 31455682
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160
[TBL] [Abstract][Full Text] [Related]
40. The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL).
Rovigatti U
Cancer Lett; 2021 Apr; 503():220-230. PubMed ID: 33271265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
